Advanced Search
Contact | Corporate | Help

EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation

Sponsors:
  • Memorial Sloan-Kettering Cancer Center
  • Genentech
  • OSI Pharmaceuticals
Phases:
IndicationsAcronym:
  • Brain Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: erlotinib
  • Drug: erlotinib
Enrollment:
22

Additional information about NCT01257594.


SourceSolution © 2008-2012